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Abstract
Passive immunisation for the prevention and 
treatment of human infectious diseases can be traced 
back to the 20th century. The recent Ebola virus outbreak 
in West Africa has turned the spotlight onto the possible 
use of convalescent whole blood and convalescent 
plasma in the treatment of infectious diseases because 
they are the only therapeutic strategy available in some 
cases, given the unavailability of vaccines, drugs or 
other specific treatments. Convalescent blood products 
could be a valid option in the treatment/prophylaxis 
of several infectious diseases both in association with 
other drugs/preventive measures and as the only therapy 
when a specific treatment is not available. However, 
there are still some issues to consider in determining the 
advisability of implementing a large-scale convalescent 
plasma transfusion programme.
Keywords: passive immunisation, emergent 
pathogens, transfusion safety, convalescent plasma, 
Ebola virus.
Introduction
Passive immunisation (PI) for the prevention and 
treatment of human infectious diseases and its related 
concept of artificially acquired passive immunity can be 
traced back to the 20th century, when specific antibodies 
were sought from serum of stimulated animals 
(especially rabbits and horses). Human blood was also 
identified as a source of antibodies1,2. PI is a technique 
to achieve immediate short-term immunisation against 
infectious agents by administering pathogen-specific 
antibodies. Since its introduction, it has proven to be 
lifesaving for many acute infections and, more recently, 
has also shown possible applications in cancer therapy1,3. 
Although antibiotics have largely supplanted the use of 
PI in bacterial infections, it remains an important tool 
in the treatment of many viral infections when vaccines 
or other specific treatments are not available. 
Convalescent blood products (CBP), obtained by 
collecting whole blood or plasma from a patient who 
has survived a previous infection and developed humoral 
immunity against the pathogen responsible for the 
disease in question, are a possible source of specific 
antibodies of human origin4. The transfusion of CBP is 
able to neutralise the pathogen and eventually leads to 
its eradication from the blood circulation. Different CBP 
have been used to achieve artificially acquired passive 
immunity1-4: (i) convalescent whole blood (CWB), 
convalescent plasma (CP) or convalescent serum (CS); 
(ii) pooled human immunoglobulin (Ig) for intravenous 
or intramuscular administration; (iii) high-titre human 
Ig; and (iv) polyclonal or monoclonal antibodies. 
CP has been the subject of increasing attention, 
especially in the wake of large-scale epidemics5. 
Apheresis plasma is currently the preferred therapeutic 
tool for several reasons: larger volumes collected per 
session, the possibility of more frequent donations, 
and the absence of impact on the donor's haemoglobin 
thanks to the reinfusion of his or her red blood cells. 
The recruitment of donors living in areas in which 
an epidemic has broken out can offer the added value 
of providing specific, artificially acquired passive 
immunity against the local infectious agent while 
CBP supplied from other regions may be less effective 
due to (possible) strain variation of the pathogen in 
question6,7. Nevertheless, the identification, selection, 
and recruitment of potential donors can be difficult, as 
convalescent subjects must also meet donor selection 
criteria, in compliance with national policies and 
routine procedures. However, because of the potential 
importance of the treatment some donor selection 
criteria, although designed to protect the donor's health, 
may be relaxed, as also suggested by the World Health 
Organization (WHO)8. Notably, the use of pathogen 
inactivation could guarantee additional safety thus 
supporting less strict selection criteria. 
Ebola virus (EBOV) is the most recent in a long 
series of infectious agents for which the WHO has 
proposed a PI-based approach8. 
The aim of this review article is to provide an 
overview on the use of CBP focusing on CP.
Historical background 
From the 1880s to the antibiotic era, CBP were used 
to prevent and treat many bacterial and viral infections in 
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humans and in animal models9. In 1890, the first rational 
approach exploited by the physiologists von Behring and 
Kitasato10 to treat diphtheria was blood serum; initially, it 
was produced from immunised animals but soon whole 
blood or serum from recovered donors with a specific 
humoral immunity were identified as a possible source 
of specific antibodies of human origin. There are several 
examples of the use of CBP for the prophylaxis or 
treatment of bacterial infectious diseases such as scarlet 
fever in the 1920-40s and pertussis until the 1970s11. 
Studies conducted during the Spanish influenza 
pandemic of 1918 to 1920 suggested that the use of 
CBP might be effective12-17 and for the first time CP 
was identified as a potential therapy for a number 
of viral infections18. In the following decades, possible 
therapeutic efficacy was claimed for the management 
of measles, Argentine haemorrhagic fever, influenza, 
chickenpox, infections by cytomegalovirus, parvovirus 
B19 and, more recently, Middle East respiratory 
syndrome coronavirus (MERS-CoV), H1N1 and H5N1 
avian flu, and severe acute respiratory infections (SARI) 
viruses19-29. Furthermore, animal models of influenza 
pneumonia have shown the benefit of CS (protection 
against H1 and H3 challenge), equine hyperimmune 
F(ab')2 globulin (protection against H5N1 challenge), 
and monoclonal antibodies (against H1, H3, and H5N1 
challenge)30-32. Interestingly, hospitalised patients with 
Lassa fever were also reported to have an apparently 
better outcome after CP administration33. Furthermore, 
a meta-analysis on Spanish influenza-CBP (involving 
8 suitable studies for a total of 1,703 patients) showed 
a significantly reduced mortality risk in the treated 
patients and suggested that CBP could be evaluated in 
the treatment of H5N1-related diseases34. 
A 2015 systematic review and exploratory post-hoc 
meta-analysis by Mair-Jenkins et al. on the effectiveness 
of CP and hyperimmune Ig for the treatment of SARI of 
viral aetiology reported a statistically significant reduction 
(75%) in the odds of mortality among SARI-affected 
patients who were treated in comparison to those who 
received a placebo or no therapy35.
Narrative analyses showed "consistent evidence 
for a reduction in mortality", especially with early CP 
administration. However, as studies were "commonly of 
low or very low quality, lacked control groups, and at 
moderate or high risk of bias", the authors claimed that 
"this therapy should be studied within the context of a 
well-designed clinical trial or other formal evaluation", 
including the treatment of MERS-CoV infection35.
As far as concerns CBP in the treatment of 
haemorrhagic fevers, in 1976 CP was used for a young 
woman infected with EBOV in the Democratic Republic 
of Congo. The woman was treated, without benefits, with 
plasma from a person who had survived an infection 
with the closely related Marburg virus36. During the 
same outbreak, 201 units of CP containing anti-EBOV 
antibodies (titre of at least 1:64) were obtained and 
frozen. Two units were transfused to an infected 
laboratory worker and the subject's recovery suggested 
the possible therapeutic effect of CP for EBOV patients37.
CP was also used to treat patients with Argentine 
haemorrhagic fever caused by the Junin virus38-41. 
In a double-blind trial carried out in 1979, patients 
treated with CP had a lower mortality rate compared to 
subjects treated with "normal plasma". An analysis of 23 
consecutive annual epidemics of Argentine haemorrhagic 
fever in a group of 4,433 patients, observed from 1959 to 
1983, showed a significant difference in overall mortality 
between patients managed with conventional treatment 
or CP (42.85% vs 3.29%)42. Immunotherapy was also 
attempted through the passive transfer of immunity 
with CP from patients who had recovered from Crimean 
Congo haemorrhagic fever, but the efficacy of this 
treatment for this disease is still not clear43.
Since the first EBOV outbreak in Congo, passive 
immunisation in infected animals (e.g. monkeys) has 
been obtained with the administration of IgG preparations 
from horses hyper-vaccinated with EBOV thus suggesting 
a potential use in humans44-47. In a 1995 outbreak in 
Kikwit, Zaire, eight patients received 150-400 mL of 
CWB and seven survived, for a mortality rate of 12.5% 
in comparison to 80% in untreated patients48. However, 
give the small number of treated patients and the lack 
of control subjects, the authors recognised the high risk 
of their work not being representative and involving 
confounding issues. In 2007, Oswald and colleagues 
reported a failure of passive transfer to protect macaques 
against challenge with EBOV49. These negative findings 
contrasted with the above mentioned claimed results 
in the treatment of EBOV infection and highlighted 
the need for better comprehension not only of the 
characteristics and titre of antibodies able to affect the 
course of diseases but also of the role of the recipients' 
immune response49. In 2012, Dye and colleagues50 
reported that passively transferred species-matched 
polyclonal IgG were able to provide total protection 
in Filovirus-challenged non-human primates as well 
as the maintenance of sufficiently high levels of 
IgG after multiple administrations until the host's 
adaptive immune responses could be recruited to 
clear the viral infection. In the same year, Olinger 
et al.51 and Qiu et al.52 reported that neutralising anti-
EBOV glycoprotein monoclonal antibodies protected 
monkeys before and after lethal virus challenge. 
Recent experience and future perspectives
In order to promote urgent research in response to 
the ongoing Ebola crisis, the European Commission's 
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Directorate-General for Research and Innovation, 
in collaboration with the WHO and the European 
Medicines Agency, has mobilised about € 25 million 
from the European Research and Innovation Programme 
Horizon 202053, launched in 2013 with funding of nearly 
€ 80 billion available over 7 years. The European Union's 
framework programme for research and support has 
mainly been focused on the development of a safe and 
effective vaccine54,55 and CBP therapies8. 
At the moment, considering the absence of licensed 
therapeutic and diagnostic tools to limit the EBOV 
outbreaks in West African countries, the WHO has 
prioritised a number of products for further investigation 
through human testing. These include two candidate 
vaccines, a short list of antiviral drugs, EBOV diagnostics, 
and CWB and CP5,8. The evaluation of the possible role 
of CP and CWB as therapeutic tools is being conducted 
through controlled clinical studies that, it is to be hoped, 
will provide evidence-based data to evaluate their safety 
and efficacy5,56. According to the WHO's criteria, only 
clinically asymptomatic survivors, 28 days after being 
discharged and who have twice tested negative for EBOV 
RNA by molecular techniques, should be considered as 
potential CBP donors8. Moreover, the discharge records of 
recovered patients should be reviewed before considering 
them as potential donors in compliance with national 
donor selection criteria. However, given the life-saving 
potential of CBP donated by survivors of this fatal 
disease, the WHO has suggested reviewing and possibly 
relaxing the donor selection criteria used in the country 
in question. Potential donors who meet the WHO criteria 
of recovery from EBOV disease and who also meet the 
donor selection criteria and have given informed consent 
should then be subjected to pre-donation testing to assess 
their final suitability for donation, according to national 
policy and routine procedures. The creation of a register 
or database of patients recovered from EBOV disease as 
potential CBP donors is strongly encouraged. A recently 
published WHO guideline provides further technical 
information on the collection and preparation of CBP, 
which should be performed by trained staff operating 
under standard operating procedures in accordance 
with international guidelines8.The WHO also dealt 
with key considerations enabling effective information, 
education, and engagement of patients recovered from 
EBOV disease and the communities in which they live, 
to consider donations of CBP for use in the treatment of 
EBOV disease and for use in clinical trials in the affected 
countries57. A WHO additional guidance document 
also deals with the ethics of using CBP during EBOV 
epidemics58.
CWB donated by patients who have recovered from 
an EBOV infection has been administered in Sierra 
Leone in a trial run by the government since late 201459. 
A phase I/II pilot clinical trial of CP began in Liberia at 
the same time and is currently recruiting patients under 
the auspices of Clinical Research Management Inc. (a 
clinical research organisation) with the USA government 
and the Bill and Melinda Gates Foundation. The study, in 
which it is intended to treat 70 EBOV-infected patients 
with 90-110 mL of CP from two ABO-compatible 
donors, will evaluate the efficacy and safety of CP and 
could provide important results as well as the answers 
to several questions regarding this still incompletely 
understood therapeutic tool60,61.
Guinea is also currently running a plasma trial 
through a partnership with institutes in Belgium, the 
UK, France, and Médecins Sans Frontières. So far, about 
100 patients have been transfused in Sierra Leone and 
Guinea. Although very recently, Gutfraind and Meyers 
suggested that CP-based therapy is not only safer but 
also more efficient than CWB therapy in reducing 
mortality62, available data from the above mentioned 
trials are currently still being analysed for definitive 
evidence of efficacy and standards are being developed.
In addition, at the end of December 2014, the 
European Blood Alliance launched a new protocol, 
developed and managed by the UK National Health 
Service Blood and Transplant (NHSBT), for the 
coordination of European stocks of EBOV CP63. 
Availability of CP from survivors in the European Union/
European Economic Area is monitored by the European 
Blood Alliance but is currently scarce and a treatment 
protocol is under development64. The German Federal 
Government has responded to the Ebola outbreak with a 
catalogue of various measures such as a study dedicated 
to the use of hyperimmune plasma undertaken by the 
Paul-Ehrlich Institute (Langen, Germany)8. 
To the best of our knowledge, at least 24 cases of 
EBOV infection have been treated in Europe and the 
USA. Many of these cases were healthcare workers who 
contracted EBOV in West Africa and were transported 
back to their home countries for treatment. Most of 
them received CP in association with multiple other 
experimental treatments and advanced supportive care. 
For American patients, investigational new drug and 
compassionate use investigational device exemption 
(for pathogen-reduced plasma) has been used as a 
mechanism to permit collection and clinical use of CP65. 
The Cerus Corporation (Concord, CA, USA) has 
recently submitted a clinical protocol to the USA Food and 
Drug Administration to allow the use of the INTERCEPT 
Blood System® for the treatment of CP collected from 
EBOV disease survivors as an additional safety measure 
to reduce the risk of any transfusion-transmitted infection 
through plasma used as passive immune therapy in 
patients with serious or life-threatening EBOV disease66. 
The same technology, for the same reason, is being used 
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in African trials. In fact, after collection, every plasma unit 
from the above donor source should undergo pathogen 
inactivation by an approved method to enhance the safety 
margin of transfused units67. In this regard, a newly 
developed process of solvent/detergent inactivation for 
use on single-donor plasma or mini-pools of plasma in 
blood establishments in developing countries68, could also 
be exploited as an additional safety tool69. 
Unfortunately, the waning of the epidemic in West Africa 
will probably have the effect of significantly reducing the 
ability to obtain useful and valid evidence-based efficacy 
data from any of the trials planned or in progress70.
Scientific uncertainties and limitations regarding 
the use of convalescent plasma
Although its efficacy and safety have not been 
fully proven yet, CP treatment could be a valid 
option in the treatment/prophylaxis of several 
infectious diseases both in association with other 
drugs/preventive measures and as the only therapy 
when a specific treatment is not available. However, 
there are still some issues to consider in determining 
the advisability of implementing a large-scale CP 
transfusion programme71: (i) the lack of high-quality 
studies (i.e. randomised clinical trials); (ii) the risk of 
transmitting infections to transfusion service personnel72 
(e.g. when handling laboratory specimens from infected 
recipients for pre-transfusion testing); (iii) the need for 
adequate selection of donors with high neutralising 
antibody titres; (iv) suitable risk assessment when 
considering relaxing the selection criteria against the 
risk impact of excluding donors; (v) case-fatality rates 
in CP trials will be influenced not only by patients' risk 
factors but also by the specific supportive care offered by 
clinical centres; (vi) immunotherapy using monoclonal 
antibodies could be more effective; (vii) many healthcare 
workers transferred to Europe or the USA received 
CP and survived but also benefited from experimental 
therapies and optimal supportive treatment, which are 
rarely available in developing countries; and (viii) in 
endemic areas, the risk of other transfusion-transmitted 
infections (e.g. human immunodeficiency virus, 
hepatitis B virus, hepatitis C virus and syphilis) cannot 
be excluded and pathogen reduction technologies should 
play a key role in guaranteeing safe CP transfusion.
Conclusions
The recent EBOV outbreak in West Africa has 
turned the spotlight onto the possible use of CBP in the 
treatment of infectious diseases because, in some cases, 
due to the unavailability of vaccines, drugs or other 
specific treatments, such blood products are the only 
therapeutic strategy available. Although many studies 
have reported the efficacy and safety of CP infusion in the 
treatment of various infections (especially those caused 
by viruses), due to the lack of large-scale, randomised, 
well-designed clinical trials, we tend to consider CP an 
"empirical" therapy. Since most of the studies conducted 
so far are case series, they can only provide us with 
low-quality scientific evidence that may or may not be 
representative of the target populations. Furthermore, it 
is worth noting that none of the studies on therapeutic 
CBP usage seems to have taken into consideration the 
possibility that such treatment could be harmful. Dengue 
is a perhaps not applicable, but certainly sobering, 
example of an infection for which immune enhancement 
of pathogenicity is considered possible73-75. In fact, this 
disease "provides the most abundant example in human 
medicine and the greatest human illness burden caused 
by the phenomenon of intrinsic antibody-dependent 
infection enhancement" which, through the infection 
of monocytes or macrophages with infectious immune 
complexes, suppresses innate antiviral systems thus 
allowing logarithmic intracellular growth of the virus76. 
This mechanism through which viruses take advantage 
of anti-viral humoral immune responses to infect host 
target cells is not limited to dengue77-79. 
Data that will be available in the near future may also 
enhance knowledge of EBOV and the characteristics 
and immune response of hosts. Information about 
the EBOV proteins targeted by the immune system 
(especially by T cells) during natural infections should 
be useful in producing effective vaccines55 and rapid 
progress in this field could make the use of obsolete, not 
advantageous CP. There may be major organisational 
and technological challenges in complying with standard 
operating procedures for the collection80, production, 
and use of CBP in developing African countries. In 
this regard, it is also worth mentioning the ethical and 
practical difficulties of designing randomised clinical 
trials on the use of CBP, particularly with respect to the 
selection of control group patients. 
Nonetheless, considering the possible seriousness 
and the high mortality rate of EBOV infection, it is 
important to provide as many people as possible a 
chance to receive safe and effective products that 
could save their lives. Collective efforts should be 
focused not only on the comprehensive evaluation 
of the feasibility of plasma treatment for infectious 
diseases but also on facilitating access to widespread 
and affordable treatments, especially in developing 
countries. Last but not least, it is important to ensure 
that the production and use of CBP take place according 
to precise ethical and controlled conditions and clinical 
trials are completed to produce the evidence base for 
a possible role of these products of human origin in 
preparedness plans for future outbreaks of emergent 
or re-emergent pathogens.
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